Start and Grow a Profitable Botox®, Aesthetic Medicine or Medical Weight Management Practice
Aesthetic Medicine Symposium
Menu
Menu
The number one most requested aesthetic procedure is for Botulinum Toxin (Botox®) injections. Merz Aesthetics offers a competitor to Botox® – Xeomin®. Xeomin® comes in 100 unit vials just like Botox® and behaves the same way as Botox®. For more information on Xeomin® for cosmetic patients, check out our information sheet.
The International Association for Physicians in Aesthetic Medicine (IAPAM) provides physicians (MD/DO’s), PAs, and NPs with comprehensive hands-on Xeomin® injection training led by board-certified cosmetic dermatologists.
The IAPAM’s offers the only Xeomin® injection training program course, where:
Make more and work less by growing a profitable aesthetics practice.
Learn the clinical and business skills you need to transform your work/life balance in just 4-days!
October 27-30 (only 3 spots left!)
in sunny Scottsdale, AZ
Xeomin has available outside the US since 2005, and was introduced in the US in 2010. Xeomin was given the FDA approval in July 2011 for the treatment of cervical dystonia, blepharospasm, and glabellar lines, but an injuction halted the release.
Now, after a 10 month injunction, Xeomin is again being launched in the US as a treatment of glabellar lines. Xeomin®, by Merz Pharmaceuticals LLC, is a competitor to the well established Botox Cosmetic® and lesser used Dysport®.
Patients are less likely to become resistant to Xeomin because there are simply less ingredients in the solution. Some patients have developed antibodies to Botox and Dysport.
Xeomin is supplied in vials containing 50 or 100 Units of incobotulinumtoxinA, 1 mg of human albumin, and 4.7 mg sucrose. Xeomin should be reconstituted with sterile, preservative-free 0.9% Sodium Chloride Injection, USP.
Reconstituted XEOMIN solution should be administered within 24 hours after dilution. During this time period, reconstituted XEOMIN should be stored in a refrigerator 2-8°C (36-46°F).
Xeomin does not need to be refrigerated prior to reconstitution and has a shelf life of 3 years.
Reconstitution instructions are provided for both vial volumes:
|
Volume of Preservative-free 0.9% Sodium Chloride Injection, USP |
50 Unit Vial: Resulting dose in Units per 0.1 mL |
100 Unit Vial: Resulting does in Units per 0.1 mL |
|
0.25 mL |
20 Units |
– |
|
0.5 mL |
10 Units |
20 Units |
|
1 mL |
5 Units |
10 Units |
|
1.25 mL |
4 Units |
8 Units |
|
2 mL |
2.5 Units |
5 Units |
|
2.5 mL |
2 Units |
4 Units |
|
4 mL |
1.25 Units |
2.5 Units |
|
5 mL |
1 Unit |
2 Units |
|
8 mL |
– |
1.25 Units |
Re-treatment with XEOMIN should be administered no more frequently than every three months.
A suitable sterile needle 30-33 gauge (0.3-0.2 mm diameter), 13 mm length should be used in the administration in the treatment of glabellar lines.
The median first onset of XEOMIN effect occurs within seven days after injection. The typical duration of effect of each treatment is 3-4 months, but effects can last up to 6 months.
The cost for Xeomin is reported to be slightly less, but roughly the same as the cost of Botox®.*
It is anticipated that the average retail cost to a patient in the US, for a Xeomin treatment, is between $100.00 – $600.00 every 3-4 months. It is dependent on the areas treated.
Scottsdale, Arizona
Botox is a trademark of Allergan Inc.; Dysport is a trademark of Galderma; Xeomin is a trademark of Merz Aesthetics
